Greater Epoetin alfa responsiveness is associated with improved survival in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 4, 2008, Pages 1077-1083

  Kilpatrick, Ryan D ^a   Critchlow, Cathy W ^a   Fishbane, Steven ^b   Besarab, Anatole ^c   Stehman Breen, Catherine ^a   Krishnan, Mahesh ^a   Bradbury, Brian D ^a  

^a AMGEN INC   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49149113180     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04601007     Document Type: Article

References (25)

1. KDOQI: Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47[Suppl]: 111-145, 2006
2. Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46: 481-488, 2005
3. Barany P, vino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29: 565-568, 1997
4. Del VL, Pozzoni P, Andrulli S, Locatelli F: Inflammation and resistance to treatment with recombinant human erythropoietin. J Renal Nutr 15: 137-141, 2005
5. Hsu SP, Peng YS, Pai MF, Hung KY, Tsai TJ: Influence of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in hemodialysis patients. Blood Purif 21: 220-224, 2003
6. Ifudu O, Fowler A: Hepatitis B virus infection and the response to erythropoietin in end-stage renal disease. ASATO J 47: 569-572, 2001
7. Ifudu O: Patient characteristics determining rHuEPO dose requirements. Nephrol Dial Transplant 17[Suppl 5]: 38-41, 2002
8. Stenvinkel P, Barany P: Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol Dial Transplant 17[Suppl 5]: 32-37, 2002
9. Tonelli M, Blake PG, Muirhead N: Predictors of erythropoietin responsiveness in chronic hernodialysis patients. ASAIO J 47: 82-85, 2001
10. Locatelli F, Conte F, Marcelli D: The impact of haernatocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity: the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13: 1642-1644, 1998
11. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haernodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132, 2004
12. Strippoli GF, Navaneethan SD, Craig JC: Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev CD003967, 2006
13. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hernatocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 339: 584-590, 1998
14. Cotter DJ, Stefanik K, Zhang Y, Thamer M: Improved survival with higher hematocrits: where is the evidence? Semin Dial 17: 181-183, 2004
15. Kaysen GA, Muller HG, Ding J, Chertow GM: Challenging the validity of the EPO index. Am J Kidney Dis 47: 166, 2006
16. Agresti A: Categorical Data Analysis, New York, John Wiley and Sons, 1990, pp 100-102
17. Eschbach JW: Anemia management in chronic kidney disease: role of factors affecting Epoetin responsiveness. J Am Soc Nephrol 13: 1412-1414, 2002
18. Tarng DC, Huang TP, Chen TW, Yang WC: Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int 69[Suppl]: 107-118, 1999
19. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004
20. Kotanko P, Levin NW, Fishbane S, Tarng DC, Berns JS: How can erythropoietin requirements be reduced in dialysis patients? Semin Dial 19: 363-372, 2006
21. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42: 761-773, 2003
22. Lin CL, Huang CC, Yu CC, Wu CH, Chang CT, Hsu HH, Hsu PY, Yang CW: Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 20: 349-356, 2002
23. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:1181-1191, 2006
24. Kaysen GA: Role of inflammation and its treatment in ESRD patients. Blood Purif 20: 70-80, 2002
25. U.S. Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.